Clinical trials: Vision, open to volunteers
Primary Open Angle Glaucoma
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with…
- Trial name
- NCT07235592
- Testing
- Microshunt XI
- Where
- 12 sites in Austria, Belgium and 6 more
- Volunteers
- 112 people
- Sponsor
- Santen SAS
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Open Angle Glaucoma
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
- Trial name
- NCT06246136
- Testing
- ELIOS, Competitor Device
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 194 people
- Sponsor
- Elios Vision, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not…
- Trial name
- NCT06769698
- Testing
- FDC fianlimab+cemiplimab, Cemiplimab
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers, Cardiometabolic Diseases
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems.
- Trial name
- NCT07797855
- Testing
- NNC0705-0002
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Glaucoma
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07495852
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Glaukos Corporation
Stargardt Disease, Retinitis Pigmentosa (RP)
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis…
- Conditions
- Stargardt Disease, Retinitis Pigmentosa (RP), Inherited Retinal Degeneration
- Trial name
- PRIMAlia (NCT07266584)
- Testing
- PRIMA Products
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Retinitis Pigmentosa
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa…
- Trial name
- ABACUS-2 (NCT06628947)
- Testing
- 100 μg KIO-301, 50 μg KIO-301
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Hyperopia, Presbyopia
The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.
The VIS Opti-K Low Vision Aid device will be used to provide vision improvement to patients with refractive disorders (hyperopia and presbyopia).
- Trial name
- Opti-K Pres (NCT06597292)
- Testing
- Vision improvement
- Where
- 2 sites in United States, Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VIS, Inc.
Presbyopia
Phase III Presbyopia Correction Using the VIS Opti-K™ System
The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low…
- Trial name
- Opti-K™ (NCT06487897)
- Testing
- Optimal laser keratoplasty
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- VIS, Inc.
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with…
- Conditions
- Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
- Trial name
- NCT06760546
- Testing
- Setmelanotide
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Age - Related Macular Degeneration (AMD)
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment.
- Trial name
- PERSPECTIVE (NCT07164378)
- Testing
- Lens-Exchange, Add-on
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- VisionCare, Inc.
Optic Neuritis
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
- Trial name
- PIONEER-1 (NCT07623668)
- Testing
- Privosegtor, Methylprednisolone
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Oculis
Retinal Dystrophies, Color Vision Defects
Natural History Study of Inherited Retinal Diseases
This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal…
- Conditions
- Retinal Dystrophies, Color Vision Defects, Vision Disorders, Macular Degeneration
- Trial name
- MojiLVCDT (NCT07085533)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Augelux Therapeutics
No Disease
A Study to Test the Repeatability and Reproducibility in Rod Intercept Time Within the AdaptDx Pro in Healthy Subjects With Normal Vision (FlashForward)
The purpose of this study is to test the repeatability and reproducibility in Rod Intercept (RI) time with two AdaptDx Pro devices in healthy subjects with normal vision.
- Trial name
- FlashForward (NCT07860905)
- Testing
- AdaptDx Pro
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AdaptDx, Inc.
Cataract Surgery, Ocular Infections
Efficacy of EPD-09-25 for Eyelid Hygiene Before and After Eye Surgery.
This is an interventional, open-label, two-arms clinical trial, randomized 1:1 (EPD treatment or no eyelid hygiene treatment) in patients scheduled for eye surgery (cataract surgery).
- Trial name
- NCT07418333
- Testing
- EPD Eyelid wipes
- Volunteers
- 100 people
- Sponsor
- VISUfarma SpA
Autosomal Recessive Polycystic Kidney (ARPKD)
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD
- Trial name
- NCT04782258
- Testing
- Tolvaptan Suspension, Tolvaptan Tablets
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.